BioCentury on BioBusiness,
Finance
Table: ASCO movers
Back to the parent article
Published on
Monday, June 11, 2012
At least 13 biotechs gained or lost 10% or more on the
week after presenting at the American Society of Clinical Oncology meeting
in Chicago. At least eight companies gained more than 10%, led by a 30% move by
Pharmacyclics Inc. (NASDAQ:PCYC). The company presented positive ORR
data from three Phase Ib/II trials of ibrutinib, a Bruton's tyrosine kinase
(Btk) inhibitor, in chronic lymphocytic leukemia (CLL), small cell lymphocytic
lymphoma (SLL), and prolymphocytic leukemia (PLL) (see B29).
At least five biotechs lost 10% or more, with Cyclacel
Pharmaceuticals Inc. (NASDAQ:CYCC) down 17%. However, the stock had gained
23% from May 16, when ASCO abstracts were released, to June 1, the start of the
conference. Shares of Dendreon Corp. (NASDAQ:DNDN) fell 13% on Monday
after multiple ASCO presentations featuring prostate cancer data from other
companies. Zytiga abiraterone from Johnson & Johnson (NYSE:JNJ) met
the
143
words displayed of
715
words total.
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Current Subscribers
If you are a current subscriber, log in below or in the upper right corner of this
page.
Log In
Subscription Option
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
records.
close [ X ]